Smarter Science. Better Outcomes.

Apogee is focused on internally developing and acquiring, intellectual property to fuel our discovery engine and therapeutic pipeline. Apogee currently has two internal drug discovery programs focused on the endocannabinoid system and has filed patent applications for both. These filings reflect Apogee’s scientific foundation and commitment to advancing therapies for significant unmet needs.

Apogee’s programs are in the preclinical stage, progressing through hit‑to‑lead and lead optimization toward development‑candidate selection. Each program is chosen and developed with a strong scientific rationale and a clear line of sight to patient needs.

Key therapeutic areas under development include:

  • Endometriosis: Endometriosis is a debilitating condition at the intersection of immune and hormonal dysregulation. Apogee is exploring therapeutic approaches that address inflammation, fibrosis, and immune dysfunction. The disease affects approximately 1 in 10 women of reproductive age worldwide, and no targeted immunotherapies are approved today, highlighting the significant unmet need. Apogee’s goal is to develop first‑in‑class, non‑hormonal treatments that alleviate symptoms and modify disease progression without the side effects of hormonal therapy.

  • Adenomyosis: Adenomyosis is a hormone‑dependent condition in which endometrial tissue infiltrates the myometrium, leading to uterine enlargement, heavy menstrual bleeding, chronic pelvic pain, and anemia. Prevalence is uncertain due to diagnostic challenges and symptomatic overlap with fibroids and endometriosis. No therapies are approved specifically for adenomyosis; management of this condition relies on off‑label hormonal suppression, and hysterectomy remains the only definitive treatment. Apogee is investigating non‑hormonal approaches that directly address major symptoms and limit endometrial tissue growth.

  • Endocannabinoid System (ECS): Apogee has been designing small‑molecule therapeutics to modulate the endocannabinoid system, a regulatory network that influences pain perception, lipid metabolism, and immune‑inflammatory responses. Apogee’s discovery efforts target key receptors and enzymes within the ECS to treat immune‑related disorders in new ways, with the potential to normalize immune and pain responses where traditional approaches have fallen short.

  • Additional Women’s Health Indications: Apogee is also evaluating other women’s health indications with large unmet need and strong potential to benefit patients, including leiomyoma, preterm birth, preeclampsia, and polycystic ovary syndrome, where scientific rationale and strategic fit are compelling.

To guide our pipeline and increase the probability of clinical success, Apogee employs Translational RubriX, our proprietary, AI‑enabled platform that integrates human genetics, multi‑omics analyses, target tractability, pharmacology, safety, tool compound availability, and competitive intelligence into an actionable knowledge framework. Translational RubriX scores and prioritizes targets based on the strength and relevance of evidence linking them to disease outcomes, enabling rational, evidence‑based selection of candidates positioned for successful clinical translation.